As the first examples, JQ1 and I-BET were developed to target the bromo- and extra-terminal domain (BET) family comprising BRD2, BRD3, BRD4 and BRDT, and their antitumor activities have been well documented along with some promising results of clinical trials for certain cancer types9–11. This evidence concerns the gene DNER and cancer.